Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study

Biol Psychiatry. 2004 Oct 15;56(8):587-91. doi: 10.1016/j.biopsych.2004.07.018.

Abstract

Background: Recurrence of depressive symptoms after tryptophan depletion (TD) in selective serotonin reuptake inhibitor (SSRI)-treated depression is an important, unexplained phenomenon. With [(18)F] MPPF positron emission tomography (PET), serotonin (5-hydroxytryptamine, 5-HT) 1A receptor binding potential (5-HT(1A)BP) was measured after TD in various brain regions in citalopram-treated depression. This 5-HT(1A)BP measurement is sensitive to changes in extracellular 5-HT in animal models.

Methods: Eight remitted patients with major depressive disorder received [(18)F] MPPF PET scans twice: once after TD and once after sham depletion. Behavioral measures were evaluated with the Hamilton Depression Rating Scale and visual analog scales.

Results: No effect on regional 5-HT(1A)BP was observed after TD, despite an 86% decrease in total plasma tryptophan and transient depressive relapse in six of eight patients.

Conclusions: Large-magnitude changes in extracellular 5-HT are not crucial for the mood effects observed in SSRI-treated subjects after TD. Therefore, greater consideration must be given to other mechanisms that involve vulnerability to small perturbations in extracellular 5-HT, such as impairment of signal transduction.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminopyridines
  • Brain / diagnostic imaging
  • Brain / drug effects
  • Brain Mapping
  • Depressive Disorder, Major / diagnostic imaging*
  • Depressive Disorder, Major / drug therapy
  • Depressive Disorder, Major / metabolism*
  • Double-Blind Method
  • Fluorine Radioisotopes
  • Humans
  • Male
  • Middle Aged
  • Piperazines
  • Positron-Emission Tomography / methods*
  • Radiochemistry / methods
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use
  • Serotonin / deficiency*
  • Tryptophan / deficiency*

Substances

  • Aminopyridines
  • Fluorine Radioisotopes
  • Piperazines
  • Serotonin Uptake Inhibitors
  • Serotonin
  • 4-(2' methoxyphenyl)-1-(2'-(N-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine
  • Tryptophan